User Guide,beta amyloid peptide 1-40

The beta amyloid peptide is a crucial focus in neuroscience research, particularly due to its significant role in the pathogenesis of Alzheimer's disease. This peptide is a protein fragment derived from the larger amyloid precursor protein (APP). While the precise function of beta-amyloid in healthy individuals is still being explored, its aggregation and deposition in the brain are strongly linked to the cognitive decline observed in Alzheimer's. Understanding the various forms and properties of this peptide is essential for developing effective therapeutic strategies.

One area of interest involves the association of beta amyloid peptide with sigma receptors, specifically the sigma-2/PGRMC1 receptor. Research has indicated that the expression of sigma-2/PGRMC1 can be upregulated by Abeta oligomers in vitro, and this receptor system appears to be dysregulated in individuals with Alzheimer's disease. This connection suggests that sigma receptors might play a role in mediating the binding of Abeta oligomers to neurons, potentially contributing to neurodegeneration.

Key Forms and Characteristics of Beta Amyloid Peptide

The beta amyloid peptide is not a single entity but rather a group of protein fragments that vary in length, typically ranging from 36 to 43 amino acids. Among the most studied forms are:

* Amyloid β 1-42 peptide (Aβ42): This is a 42-amino acid peptide and is considered the predominant amyloid β-peptide found in the amyloid plaques associated with Alzheimer's disease. Its tendency to aggregate and form toxic oligomers and fibrils makes it a primary target for research. The molecular formula for beta-Amyloid Peptide (1-42) (human) is C203H311N55O60S, with a molecular weight of approximately 4514 g/mol. It is often supplied as a chloride salt and is known to be hygroscopic.

* Amyloid β 1-40 peptide (Aβ40): This is a 40-residue peptide and is another significant form of beta-amyloid. While less prone to aggregation than Aβ42, it is still implicated in the pathogenesis of Alzheimer's disease and aged Down's Syndrome.

* Beta-Amyloid Peptide (25-35): This fragment, also known as Aβ25-35, is particularly interesting as it functions as a neurotoxic agent in neuronal cell cultures. It exhibits pronounced neurotoxicity in various neural cell models and is involved in the pathogenesis of Alzheimer's disease. The molecular weight of beta-Amyloid Peptide (25-35) (human) is approximately 1060.3 Da, with a molecular formula of C45H81N13O14S. This fragment is considered highly toxic, potentially showing greater neurotoxicity than Aβ40 and Aβ42.

Other forms, such as beta-Amyloid Peptide (1-43), with a molecular weight of 4615.19 g/mol, have also been identified and studied for their toxicological profiles.

Research and Product Availability

The scientific community actively researches the role of beta amyloid peptide in neurodegenerative diseases. Companies specializing in biochemicals and research reagents, such as Merck and MilliporeSigma, offer various beta amyloid peptide products for scientific investigation. These include specific peptide sequences like amyloid β 1-42 peptide and beta amyloid peptide 1-40, often characterized by high purity. For example, PP69 Sigma-Aldrich β-Amyloid Peptide (1-42), Human is a commercially available product. Researchers can obtain both monomeric forms and pre-formed fibrils or oligomers to study different stages of aggregation and their cellular effects.

Beta Amyloid's Role in Alzheimer's Disease

The prevailing hypothesis in Alzheimer's disease research is that the production and deposition of the beta amyloid peptide drive the disease's pathology. The accumulation of these peptides in the brain leads to the formation of senile plaques and diffuse deposits, which are characteristic hallmarks of Alzheimer's disease. These deposits are believed to disrupt normal neuronal function, leading to inflammation, synaptic dysfunction, and ultimately, neuronal death. The beta amyloid peptide has been proposed to affect neuronal degeneration, and its aggregation is a central event in the cascade leading to the cognitive impairments associated with Alzheimer's.

In summary, the beta amyloid peptide is a critical molecule in understanding Alzheimer's disease. Its various forms, particularly Aβ42 and Aβ25-35, exhibit significant neurotoxicity and are implicated in disease pathogenesis. Ongoing research into its interactions, such as with sigma receptors, and the development of therapeutic agents targeting its aggregation and deposition are vital steps towards finding effective treatments for this debilitating condition.